Description:
20-25% of patients over 15 years with acute lymphoblastic leukemia (ALL) have the
Philadelphia chromosome or BCR-ABL rearrangement. Traditionally, intensive chemotherapy
followed by hematopoietic stem cell transplantation (HSCT) have formed the basis allogeneic
treatment of this disease, but the results have been poor (60-75% complete remissions-RC-and
probability of long-term survival less than 20%). The effectiveness of imatinib for
hematologic responses in patients with Ph + (observed in phase I and II) led to its use in
phase III trials in combination with chemotherapy. They saw a chance of obtaining the RC
above 90%, with acceptable toxicity, a molecular response rate (MR) of 40-50%, and prolonged
follow-up studies, a probability of disease-free survival (DFS ) of 30-50%, significantly
higher than historical controls with the same chemotherapy without imatinib. This led to the
approval of imatinib by the rating agencies in the U.S., Europe and Japan as a treatment for
Ph + in combination with chemotherapy.
Of the studies that led to the approval of this indication for imatinib, and other incurred
after, the following conclusions can be drawn:
There is no specific pattern of combination of imatinib (at doses of 600 mg / day, po) and
chemotherapy. However, when compared with concomitant alternating with the first achieved a
higher rate of RM at the end of induction, although this did not influence DFS.
In studies in elderly patients has achieved a high CR rate (almost 100% in all series), only
imatinib and glucocorticoids, suggesting that an attenuated induction may be sufficient to
achieve CR in young patients with minimal toxicity, which further compromises the
administration of treatment and allow for an allogeneic HSCT with minimal toxic load
possible.
Although there is no consensus on the indication of allogeneic HSCT in first CR when given
imatinib associated with intensive chemotherapy is an option that is done in most studies.
The allogeneic HSCT is most effective when carried out in complete molecular response to or
greater than when there is more residual disease. However, the impact of MRI to obtain early
(after induction) on survival is not clear. So far-reaching goal is to make the TPH in
complete molecular response situation or greater.
The relapse of the disease at the molecular level is still short-term (less than 3 months) of
hematological relapse. This implies the need for frequent monitoring of residual disease (ER)
The frequency of relapse post HSCT is high (around 30%), raising the need for any post HSCT
treatment, including imatinib included. Are currently ongoing clinical trials comparing the
systematic administration of imatinib after administration TPH face is detected only when ER.
The applicability of the administration of imatinib after HSCT is limited by toxicity related
to the procedure of TPH, is making frequent dose reduction or discontinuation.
Therefore, a reasonable approximation treatment of Ph + outside the context of a clinical
trial is to get as many molecular responses before allogeneic HSCT in a position to make the
same MRI complete or greater. After TPH, must be very close monitoring of the ER, and
imatinib is administered as soon as you notice the loss of molecular response.
In patients who can not make an allogeneic HSCT for lack of histocompatible donor or
contraindications for its realization it is recommended imatinib and chemotherapy, although
there are studies that have undergone an autologous HSCT, followed or not treatment
"maintenance" with imatinib. The low toxicity of autologous HSCT and no effect of graft
versus leukemia are strongly recommended the administration of maintenance therapy with
imatinib combined with chemotherapy or not.
Title
- Brief Title: Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE
- Official Title:
Clinical Trial IDs
- ORG STUDY ID:
LAL Ph-2008
- NCT ID:
NCT01491763
Conditions
- Acute Lymphoblastic Leukemia Ph Positive
Interventions
Purpose
20-25% of patients over 15 years with acute lymphoblastic leukemia (ALL) have the
Philadelphia chromosome or BCR-ABL rearrangement. Traditionally, intensive chemotherapy
followed by hematopoietic stem cell transplantation (HSCT) have formed the basis allogeneic
treatment of this disease, but the results have been poor (60-75% complete remissions-RC-and
probability of long-term survival less than 20%). The effectiveness of imatinib for
hematologic responses in patients with Ph + (observed in phase I and II) led to its use in
phase III trials in combination with chemotherapy. They saw a chance of obtaining the RC
above 90%, with acceptable toxicity, a molecular response rate (MR) of 40-50%, and prolonged
follow-up studies, a probability of disease-free survival (DFS ) of 30-50%, significantly
higher than historical controls with the same chemotherapy without imatinib. This led to the
approval of imatinib by the rating agencies in the U.S., Europe and Japan as a treatment for
Ph + in combination with chemotherapy.
Of the studies that led to the approval of this indication for imatinib, and other incurred
after, the following conclusions can be drawn:
There is no specific pattern of combination of imatinib (at doses of 600 mg / day, po) and
chemotherapy. However, when compared with concomitant alternating with the first achieved a
higher rate of RM at the end of induction, although this did not influence DFS.
In studies in elderly patients has achieved a high CR rate (almost 100% in all series), only
imatinib and glucocorticoids, suggesting that an attenuated induction may be sufficient to
achieve CR in young patients with minimal toxicity, which further compromises the
administration of treatment and allow for an allogeneic HSCT with minimal toxic load
possible.
Although there is no consensus on the indication of allogeneic HSCT in first CR when given
imatinib associated with intensive chemotherapy is an option that is done in most studies.
The allogeneic HSCT is most effective when carried out in complete molecular response to or
greater than when there is more residual disease. However, the impact of MRI to obtain early
(after induction) on survival is not clear. So far-reaching goal is to make the TPH in
complete molecular response situation or greater.
The relapse of the disease at the molecular level is still short-term (less than 3 months) of
hematological relapse. This implies the need for frequent monitoring of residual disease (ER)
The frequency of relapse post HSCT is high (around 30%), raising the need for any post HSCT
treatment, including imatinib included. Are currently ongoing clinical trials comparing the
systematic administration of imatinib after administration TPH face is detected only when ER.
The applicability of the administration of imatinib after HSCT is limited by toxicity related
to the procedure of TPH, is making frequent dose reduction or discontinuation.
Therefore, a reasonable approximation treatment of Ph + outside the context of a clinical
trial is to get as many molecular responses before allogeneic HSCT in a position to make the
same MRI complete or greater. After TPH, must be very close monitoring of the ER, and
imatinib is administered as soon as you notice the loss of molecular response.
In patients who can not make an allogeneic HSCT for lack of histocompatible donor or
contraindications for its realization it is recommended imatinib and chemotherapy, although
there are studies that have undergone an autologous HSCT, followed or not treatment
"maintenance" with imatinib. The low toxicity of autologous HSCT and no effect of graft
versus leukemia are strongly recommended the administration of maintenance therapy with
imatinib combined with chemotherapy or not.
Detailed Description
Induction Chemotherapy
- Vincristine (VCR): 1.5 mg/m2 (maximum dose 2 mg) iv days 1, 8, 15 and 22
- daunorubicin (DNR) 45 mg/m2 i.v. days 1, 8, 15 and 22
- Prednisone (PDN): 60 mg/m2 per day, i.v. or p.o., days 1-27
- Imatinib 600 mg p.o. from day 1 until the beginning of the consolidation. Important
Note: The administration of imatinib be initiated as soon as the outcome of cytogenetic
and molecular study, which will be known under normal conditions during prophase
consolidation
Patients should be in RC and shall be a minimum of 2 weeks of finding it. Patients did not
discontinue treatment with imatinib during this period. Minimum counts to start the
consolidation are: neutrophils> 1x109 / L and platelets> 100x109 / L.
- Mercaptopurine (MP) 50 mg/m2, p.o. days 1 to 7, 28 to 35 and 56 to 63
- MTX: 1.5 g/m2, i.v. continuous infusion for 24 hours on days 1, 28 and 56.
- VP-16: 100 mg/m2 every 12 hours, i.v. (1 hour infusion) on days 14 and 42
- ARA-C: 1000 mg/m2 every 12 hours, i.v. (3-hour infusion) days 14-15 and 42-43
- triple intrathecal treatment days 1, 28 and 56
- Imatinib 600 mg / d po, from day 1 to 15 days before the TPH.
During consolidation therapy is recommended in primary prophylaxis with G-CSF or found
neutropenia (<0.5 x109 / L). This factor was administered daily until the neutrophil count is
> 1x109 / L in two consecutive measurements. Alternatively, PEG-filgrastim can be used (eg 16
and 44), at the discretion of each center
Allogenic THP or Autologous TPH
Trial Arms
Name | Type | Description | Interventions |
---|
Eligibility Criteria
Inclusion Criteria:
- Patients with Ph (BCR/ABL) positive de novo < 55 years old (it is advisable to include
patients over 55 years LAL07OPH protocol).
- Performance status 0-2 (Appendix B) may include patients with performance status > 2
attributable to LAL.
- Patients without functional impairment of organs: liver function: total bilirubin,
AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal
laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30
ml/min (except renal function attributable to LAL) cardiac function (Appendix B)
normal: ventricular EF > 50%, absence of severe chronic respiratory disease. In the
event that alterations are secondary to the disease is at the discretion of the
investigator to determine if the patient can be included in the trial.
Exclusion Criteria:
- Any other variety of LAL
- Patients with a history of coronary artery disease, valvular or hypertensive heart
disease
- Patients with chronic liver disease
- Patients with chronic respiratory failure
- Renal failure not due to LAL
- Patients with positive HIV status
- No serious neurological abnormalities due to LAL
- Impact on overall severe (grade 3 or 4 of the WHO scale) not attributable to the LAL
- Pregnant or breastfeeding
- initial blast crisis CML
Maximum Eligible Age: | 55 Years |
Minimum Eligible Age: | N/A |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Efficacy in terms of number of complete response |
Time Frame: | 1 year |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 4 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | PETHEMA Foundation |
Last Updated
January 15, 2021